Daily Ards Research Analysis

BACKGROUND: Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are multifaceted clinical conditions characterized by uncontrolled inflammatory responses and compromised integrity of the alveolar-capillary barrier. The lack of specific diagnostic tests and effective pharmacologic therapies for ARDS reflects its underlying biological heterogeneity. In sepsis, the excessive formation of neutrophil extracellular traps (NETs) contributes to ALI pathogenesis by inducing endothelial injury, increasing vascular permeability, and amplifying pulmonary inflammation. This meta-analysis integrates findings from clinical and preclinical studies to elucidate disease pathogenesis and inform diagnostic strategies. METHODS: A systematic search of PubMed, Google Scholar, and the Cochrane Library was conducted following predefined inclusion and exclusion criteria. The primary outcome measure was the standardized mean difference with a 95% confidence interval, assessed using a random-effects model. RESULTS: We identified a significant upregulation of NETs and their related components, including myeloperoxidase (MPO), the MPO-DNA complex, neutrophils, citrullinated histone H3 (citH3), cell-free DNA (cfDNA), double-stranded DNA (dsDNA), and peptidylarginine deiminase 4 (PAD4) in preclinical models. Furthermore, we validated the elevated expression of NETs, cfDNA, dsDNA, and the MPO-DNA complex in patients with ALI/ARDS. CONCLUSION: This meta-analysis identified key NET-associated biomarkers that are dysregulated in both patients with ALI and experimental models. These biomarkers are involved in disease pathophysiology and have the potential to serve as diagnostic indicators. These outcomes contribute to a deeper understanding of NET-mediated mechanisms in ALI and support the need for further research on NET-targeted diagnostic approaches and therapeutic strategies.

Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are severe complications following hemorrhagic shock, leading to significant morbidity and mortality. Direct peritoneal resuscitation (DPR) has been proposed to improve microcirculation and reduce organ damage, but its effects on lung injury have not yet been fully explored. Does direct peritoneal resuscitation with peritoneal dialysis fluid (PDF) reduce lung injury in a controlled hemorrhagic shock model in rats? In this randomized experimental study, 32 male Wistar albino rats were randomly assigned to four groups (n = 8 per group). Group I served as the control group, while Groups II, III, and IV underwent hemorrhagic shock. Group III received peritoneal resuscitation with saline, and Group IV received PDF. Lung tissue samples were harvested after 24 h to assess histopathological damage and inflammatory markers; Interleukin-6 (IL-6), interleukin-10 (IL-10), and tumor necrosis factor-alpha (TNF-α) levels. DPR with PDF significantly attenuated lung injury compared to saline-treated or hemorrhagic shock-only groups. Interstitial polymorphonuclear leukocytes (PMNL) infiltration and alveolar septal thickening were reduced in the DPR group. Additionally, IL-6 levels were elevated in the DPR group, suggesting a potentially enhanced localized inflammatory response, while no significant differences were found in IL-10 and TNF-α levels. Direct peritoneal resuscitation with PDF was effective in reducing lung injury in rats subjected to hemorrhagic shock by improving microcirculatory function and modulating the inflammatory response. However, the elevated IL-6 levels suggest further investigation is needed to understand the long-term implications of this inflammatory response.

Inflammatory lung diseases, including community-acquired pneumonia, acute respiratory distress syndrome (ARDS), severe viral pneumonia (including COVID-19), ventilator-associated pneumonia, and exacerbations of chronic obstructive pulmonary disease (COPD), necessitate prompt diagnostic and prognostic assessments accompanied by microbiological confirmation of the causative pathogen. Conventional biomarkers, including C-reactive protein and procalcitonin, are insufficient to distinguish between localized pulmonary and systemic inflammation. This narrative review summarizes the studies on Pentraxin-3 (PTX3), a locally synthesized, extrahepatic acute-phase protein secreted by endothelial cells, epithelial cells, and myeloid leukocytes at sites of inflammation, as a diagnostic and prognostic biomarker in the continuum of inflammatory lung diseases. Plasma PTX3 indicates systemic endothelial activation and disease severity, whereas bronchoalveolar lavage PTX3 concentrations provide compartment-specific diagnostic data, identify follow-up infections, and allow therapeutic escalation in relation to the disease phenotype. Nevertheless, clinical laboratory implementation involves matrix-specific reference levels, analytical validation containing limits of detection/quantification, precision, linearity, and interfering studies according to CLSI, commutable calibrators, and traceability hierarchies. The pre-analytical procedure is standardized, and platform-independent decision limits through harmonized assays, preparation of external quality assessment, and compatibility of acute-care turnaround times are required to implement multicenter PTX3 in routine clinical laboratory diagnostics.